Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03542110 · ClinicalTrials.gov registry record · Phase 4
The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial
A Phase 4 study, sponsored by Minneapolis Heart Institute Foundation.
- Terminated
- Registry status
- Phase 4
- Development phase
- 46
- Enrollment target
NCT03542110 is a Phase 4 study that was terminated before completion, run by Minneapolis Heart Institute Foundation. The registered enrollment target is 46 participants.
The verdict
NCT03542110, a Phase 4 study, was terminated before completion, sponsored by Minneapolis Heart Institute Foundation.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 46 participants
- Enrollment target
Study Summary
This is a phase IV, multi-center, double-blind, randomized, placebo- controlled study evaluating the effect of alirocumab on SVG atherosclerotic disease burden, as assessed by IVUS at baseline and following 78 weeks of treatment in subjects with at least one intermediate SVG lesion receiving optimal statin therapy. Subjects will be randomized 1:1 into 2 treatment groups: alirocumab 150 mg subcutaneously every 2 weeks or placebo subcutaneously every 2 weeks.
Interventions
- DRUG Alirocumab 150 MG/ML subcutaneous injection
- DRUG Matching Placebo subcutaneous injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2018-08-04 |
| Est. Completion | 2020-07-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03542110
The ClinicalTrials.gov registry entry for NCT03542110 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Minneapolis Heart Institute Foundation, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Alirocumab 150 MG/ML subcutaneous injection is the first listed.
NCT03542110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03542110 about?
NCT03542110 is a clinical study titled "The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial". This is a phase IV, multi-center, double-blind, randomized, placebo- controlled study evaluating the effect of alirocumab on SVG atherosclerotic disease burden, as assessed by IVUS at baseline and following 78 weeks of treatment in subjects with at least one intermediate SVG lesion receiving optimal...
What is the current status of trial NCT03542110?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 46 participants. The study started on 2018-08-04. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT03542110?
The interventions under investigation include: Alirocumab 150 MG/ML subcutaneous injection (DRUG), Matching Placebo subcutaneous injection (DRUG).
Who is sponsoring clinical trial NCT03542110?
This trial is sponsored by Minneapolis Heart Institute Foundation, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.